. 2023 Jul 6;14:1228962. doi: 10.3389/fphar.2023.1228962

TABLE 1.

Some small molecule inhibitors that affect transcription, translation, or posttranslational modifications to downregulate CD47-SIRPα signaling. RRx-001, metformin, 4-methylumbel ketone (4-Mu), JQ1, gefitinib and statins reduced CD47 expression by affecting transcription or translation processes. QPCTL regulates the formation of CD47 pyroglutamate, thereby facilitating its binding to SIRPα. At present, inhibitors that regulate QPCTL include SEN177 and PQ912 has entered clinical trials as a candidate for Alzheimer's disease. It has been proved that QPCTL inhibitors can block the recognition effect of CD47 on SIRPα and restore phagocytic function of macrophages, and enhance the anti-tumor effect in vivo.

Compound name	Action mechanism	Indication
RRx-001	Downregulated protein expression	Small cell lung cancer
Metformin	Downregulated protein expression	Breast cancer
4Mu	Downregulated protein expression	HCC
JQ1	Downregulated protein expression	Lymphoma
Gefitinib	Downregulated protein expression	NSCLC
Statins	Downregulated protein expression	Atherosclerosis
PQ912	Affect protein post-translational modification	Melanoma
SEN177	Affect protein post-translational modification	Melanoma